Equity · Healthcare
LGND
Ligand Pharmaceuticals Incorporated · NasdaqGM
The line runs $262.10 on 22 June through $289 on 10 September, on a scale from $260 to $340. Days the market did not trade hold the previous close, flat.
The chart above plots the price of LGND over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 43 sessions over that window: $262.10 on 22 June 2026 through $289 on 10 September 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 20, 2026
LGND insider trades
LGND has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 December 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
LGND reported financials
LGND reported revenue of $268.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was $124.5M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
LGND earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
LGND institutional holders
5 of the 45 institutional funds we track reported a LGND position for the quarter ended 30 Jun 2026 — a combined $66.8M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
LGND fails-to-deliver
On 31 Aug 2026, 1,681 shares of LGND failed to deliver (about $472K) — the latest of 2 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data
Congressional trades in LGND
The most recent congressional trade disclosed in LGND is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 Jan 2026.
Source: U.S. House of Representatives financial disclosures